AmifostineCAS# 20537-88-6 |
- Nutlin-3a chiral
Catalog No.:BCC1812
CAS No.:675576-98-4
- p53 and MDM2 proteins-interaction-inhibitor chiral
Catalog No.:BCC1830
CAS No.:939981-37-0
- p53 and MDM2 proteins-interaction-inhibitor racemic
Catalog No.:BCC1831
CAS No.:939983-14-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 20537-88-6 | SDF | Download SDF |
| PubChem ID | 2141 | Appearance | Powder |
| Formula | C5H15N2O3PS | M.Wt | 214.22 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | WR2721 | ||
| Solubility | H2O : ≥ 40 mg/mL (186.72 mM) DMF : < 1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-(3-aminopropylamino)ethylsulfanylphosphonic acid | ||
| SMILES | C(CN)CNCCSP(=O)(O)O | ||
| Standard InChIKey | JKOQGQFVAUAYPM-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Amifostine Dilution Calculator
Amifostine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.6681 mL | 23.3405 mL | 46.681 mL | 93.362 mL | 116.7025 mL |
| 5 mM | 0.9336 mL | 4.6681 mL | 9.3362 mL | 18.6724 mL | 23.3405 mL |
| 10 mM | 0.4668 mL | 2.334 mL | 4.6681 mL | 9.3362 mL | 11.6702 mL |
| 50 mM | 0.0934 mL | 0.4668 mL | 0.9336 mL | 1.8672 mL | 2.334 mL |
| 100 mM | 0.0467 mL | 0.2334 mL | 0.4668 mL | 0.9336 mL | 1.167 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Amifostine is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. Target: Others Amifostine has been shown to specifically protect normal tissues from damage caused by radiation and chemotherapy. An inactive prodrug, amifostine is converted to an active thiol by dephosphorylation by alkaline phosphatase in the normal endothelium. The cytoprotective mechanism of amifostine is complicated, involving free-radical scavenging, DNA protection and repair acceleration, and induction of cellular hypoxia. amifostine has potential applications in many other oncologic settings [1].
References:
[1]. Kouvaris, J.R., V.E. Kouloulias, and L.J. Vlahos, Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist, 2007. 12(6): p. 738-47.
- DL-TBOA
Catalog No.:BCC5735
CAS No.:205309-81-5
- Isonardoperoxide
Catalog No.:BCN7628
CAS No.:205248-65-3
- 2'-MeCCPA
Catalog No.:BCC7311
CAS No.:205171-12-6
- (+)-Peusedanol
Catalog No.:BCC9119
CAS No.:20516-23-8
- Lansiumarin C
Catalog No.:BCN4895
CAS No.:205115-75-9
- Lansiumarin A
Catalog No.:BCN4894
CAS No.:205115-73-7
- Talatisamine
Catalog No.:BCN5403
CAS No.:20501-56-8
- 3,7,4'-Trihydroxy-5-methoxy-8-prenylflavanone
Catalog No.:BCN1503
CAS No.:204935-85-3
- Curzerenone
Catalog No.:BCN3009
CAS No.:20493-56-5
- Nardosinonediol
Catalog No.:BCN8118
CAS No.:20489-11-6
- Procumbide
Catalog No.:BCN3932
CAS No.:20486-27-5
- 8-O-Acetyltorilolone
Catalog No.:BCN7094
CAS No.:20482-21-7
- Pinocembrin 7-O-(3'-galloyl-4',6'-(S)-hexahydroxydiphenoyl)-beta-D-glucose
Catalog No.:BCN6769
CAS No.:205370-59-8
- BU 224 hydrochloride
Catalog No.:BCC6765
CAS No.:205437-64-5
- Taxezopidine G
Catalog No.:BCN6947
CAS No.:205440-22-8
- Paederoside
Catalog No.:BCN3437
CAS No.:20547-45-9
- Rauvovertine B
Catalog No.:BCN7726
CAS No.:2055073-72-6
- Rauvovertine C
Catalog No.:BCN7727
CAS No.:2055073-74-8
- Rauvovertine A
Catalog No.:BCN7728
CAS No.:2055073-75-9
- Fmoc-D-Phe(3-Cl)-OH
Catalog No.:BCC3170
CAS No.:205526-23-4
- Fmoc-D-Phe(4-I)-OH
Catalog No.:BCC3262
CAS No.:205526-29-0
- Fenfangjine G
Catalog No.:BCN3297
CAS No.:205533-81-9
- 2'',4''-Di-O-(Z-p-coumaroyl)afzelin
Catalog No.:BCN4676
CAS No.:205534-17-4
- Parthenolide
Catalog No.:BCN4896
CAS No.:20554-84-1
Protective effect of amifostine on busulfan induced DNA damage in human hepatoma cells.[Pubmed:27771991]
Toxicol Mech Methods. 2017 Jan;27(1):52-57.
Busulfan is one of the most effective chemotherapeutic agents used for the treatment of chronic myeloid leukemia. However, as a bifunctional alkylating agent, during clinical use several side effects may occur. In addition, several in vivo and in vitro studies of busulfan have shown a range of genotoxic effects including DNA strand break and inhibition of DNA synthesis. Amifostine, an organic thiophosphate compound, has been shown to exert an important cyto-protective effect in many tissues. The aim of this study was to explore whether Amifostine protects against busulfan-induced genotoxicity in HepG2 cell line. Our results showed that Amifostine reduced the genotoxic effects of busulfan significantly in both type of experiment conditions, as measured via comet assay. Furthermore, Amifostine decreased the intracellular ROS generation induced by busulfan and also increased the intracellular GSH levels in HepG2 cells. Altogether, our results suggest a protective action of Amifostine against busulfan cytotoxicity and genotoxicity via various pathways. The most protective effect was observed with Amifostine when it was administrated 24 h before busulfan treatment.
CCND1-BCL2 Gene Network: A direct target of Amifostine in human acute megakaryocytic leukemia cells.[Pubmed:27762064]
Chem Biol Drug Des. 2017 May;89(5):681-693.
Amifostine, 2-(3-aminopropyl) aminoethyl phosphorothioate, is a broad-spectrum cytoprotective agent used to treat nuclear radiation and chemical weapon injuries. Recently, Amifostine has been shown to have a profound biological influence on tumor cells. To examine the effects and mechanisms underlying the effects of Amifostine on human acute megakaryocytic leukemia, we evaluated the efficacy of Amifostine against Dami cells and observed a cell cycle arrest in G2 /M phase. Amifostine treatment also induced cell apoptosis of Dami cells which corresponds to formal studies. Through whole-genome microarray and bioinformatics analyses, we found that Amifostine affected the gene expression of CCND1, BCL2, and CASP3 which revealed the mechanism Amifostine acted on Dami cells. Thus, CCND1-BCL2 Gene Network is predicted to be a direct target of Amifostine treating human acute megakaryocytic leukemia, which may provide a novel potential target for the therapy of several subtypes of human AML.
Histopathological and biochemical comparisons of the protective effects of amifostine and l-carnitine against radiation-induced acute testicular toxicity in rats.[Pubmed:28000945]
Andrologia. 2017 Nov;49(9).
The aim of this study was to compare the radioprotective efficacies of Amifostine (AMI) and l-carnitine (LC) against radiation-induced acute testicular damage. Thirty Wistar albino rats were randomly assigned to four groups: control (n = 6), AMI plus radiotherapy (RT) (n = 8), LC plus RT (n = 8) and RT group (n = 8). The rats were irradiated with a single dose of 20 Gy to the scrotal field. LC (300 mg/kg) and AMI (200 mg/kg) were given intraperitoneally 30 min before irradiation. The mean seminiferous tubule diameters (MSTDs) were calculated. Testicular damage was evaluated histopathologically using Johnsen's mean testicular biopsy score criteria. Malondialdehyde (MDA) and glutathione levels were measured in tissue samples. AMI plus RT and LC plus RT groups had significantly higher MSTDs than those in the RT group (p = .003 and p = .032 respectively). MDA values of both AMI plus RT and LC plus RT groups were significantly lower than those in RT group (p < .004 and p < .012 respectively). As a result, AMI and LC have a similar radioprotective effect against radiation-induced acute testicular damage, histopathologically and biochemically.
Sustained-release microspheres of amifostine for improved radio-protection, patient compliance, and reduced side effects.[Pubmed:27855533]
Drug Deliv. 2016 Nov;23(9):3704-3711.
A biweekly administration of sustained-release microsphere dosage form of Amifostine, a radioprotective drug used in radiotherapy, was performed to examine the feasibility to minimize injection frequency and blood concentration-associated side effects. Model animal trials indicated that this subcutaneously injecting microspheres, 50-100 mum in diameter, achieved bi-weekly prolonged radio-protective efficacy and, at the same time, significantly reduced skin irritation than the solution form of Amifostine given by the same administration route. In addition, the hypertension associated with blood concentration of Amifostine was not observed in the drug-treated rats. The animals given the Amifostine microspheres and Amifostine showed significantly differences in white blood cell, red blood cell, hematocrit, hemoglobin and spleen tissue histopathology after exposed under a cobalt-60 gamma-radiation at a dose rate of 1.0 Gy/min for 6 min. The in vitro release profile of Amifostine from the micropsheres showed a minor initial burst (less than 20% of total drug loading in the first day of administration), consisting with the side effects observations. The results suggest that Amifostine encapsulated in sustained-release microspheres may be an ideal dosage form for prolonged radio-protective efficacy and improved patient compliance.
